Maynard Um
-
-
-
-
-
-
-
Cardiol Therapeutics surpasses 50% enrollment in phase III trial
-
-
-
-
-
-
-
Cardiol Therapeutics Announces Bought Deal Financing for Gross Proceeds of $13.5 Million
-
-
-
-
-
-
-
New Data from the Phase II ARCHER Trial Demonstrate CardiolRx(TM) Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions
-
-
-
-
-
-
-
Brookline Capital Markets Starts Cardiol Therapeutics (CRDL) at Buy, PT $6
-
-
-
-
-
-
-
Cardiol Therapeutics Reports Results of 2025 Annual General Meeting of Shareholders
-
-
-
-
-
-
-
Cardiol Therapeutics (CRDL) Issues Year-end Update on Operations
-
-
-
-
-
-
-
Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024
-
443,991 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

